Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CRANBURY, N.J., May 14, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced...
-
Positive 12- and 24-Month Data From First Phase 3 Fabry Monotherapy Study (Study 011) – Results from Second Phase 3 Fabry Monotherapy Study (Study 012) Expected 3Q14 3-in-3 Strategy to...
-
Migalastat Demonstrated Statistically Significant (p=0.013) and Durable Substrate Reductions on 12-Month Pre-Specified Primary Analysis in Fabry Patients with Amenable Mutations Statistically...
-
CRANBURY, N.J., March 27, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced...
-
Executing 3-in-3 Strategy to Advance 3 Next-Generation ERTs into Clinic in Next 3 Years Reiterating FY14 Cash Spend Guidance of $54-$59 Million CRANBURY, N.J., March 3, 2014 (GLOBE NEWSWIRE) --...
-
CRANBURY, N.J., March 3, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced the...
-
CRANBURY, N.J., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced...
-
CRANBURY, N.J., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Monday, March 3, 2014 at 5:00 p.m. ET to discuss...
-
First Scientific Meeting to Present Preclinical Proof-of-Concept Data for Next-Generation Pompe ERT and Proprietary Enzyme Targeting Technology Encouraging Additional Post-Hoc Analyses of Interim...
-
CRANBURY, N.J., Feb. 11, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced...